An interventional study of MicroRepair ABX mouthwash and Chlorhexidine 0.12% mouthwash in Gingivitis, Dental Plaque and Gingival Inflammation, sponsored by University of Pavia. Completed at 1 site in Italy. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-04-23.
Sponsored by University of Pavia · Not applicable, Interventional, and Treatment
This randomized controlled clinical trial is designed to compare the adjunctive effects of two mouthwashes used after professional biofilm removal in patients with generalized plaque-induced gingivitis, a reversible inflammatory condition caused by dental plaque accumulation. The two interventions under investigation are a 0.12% chlorhexidine (CHX) mouthwash, commonly used as a reference antiseptic, and a MicroRepair® ABX mouthwash containing a multi-component antibacterial complex composed of cetylpyridinium chloride, magnolol, and honokiol, combined with biomimetic hydroxyapatite.
All participants will receive standardized professional oral hygiene treatment according to the Guided Biofilm Therapy (GBT) protocol. Following this procedure, participants will be randomly assigned to one of the two study groups and instructed to use the allocated mouthwash twice daily for 14 days as an adjunct to routine oral hygiene.
Clinical outcomes will include measures of gingival inflammation and plaque accumulation, such as Full-Mouth Bleeding Score (FMBS) and Full-Mouth Plaque Score (FMPS), along with additional periodontal parameters (probing pocket depth, clinical attachment level, and gingival recession). Treatment-related effects such as tooth staining and dentinal hypersensitivity will also be evaluated. A biological outcome will be assessed through the measurement of salivary levels of active matrix metalloproteinase-8 (aMMP-8), a biomarker associated with periodontal inflammation. Patient-reported outcomes, including perceptions of gingival condition, oral comfort, and taste acceptability, will also be collected.
Participants will be followed for 6 months. The study aims to determine whether the MicroRepair® ABX mouthwash provides clinical, biological, and patient-reported outcomes comparable to those of chlorhexidine when used as an adjunct to professional biofilm removal in the management of plaque-induced gingivitis.
Gingivitis is the most common reversible form of periodontal disease and is primarily caused by the accumulation of bacterial biofilm along the gingival margin. Chlorhexidine digluconate is widely used as an adjunct to professional oral hygiene; however, its use may be associated with adverse effects such as tooth staining, taste alteration, and mucosal irritation. In recent years, alternative formulations combining antibacterial agents and biomimetic hydroxyapatite have been investigated for their potential role in plaque control and gingival inflammation management.
This randomized, controlled, monocentric clinical trial aims to compare the clinical and biological effects of a mouthwash containing a multi-component antibacterial complex (MicroRepair® ABX), composed of cetylpyridinium chloride, magnolol, and honokiol combined with biomimetic hydroxyapatite, with those of a 0.12% chlorhexidine (CHX) mouthwash in patients with generalized plaque-induced gingivitis. Forty adult participants will be randomly assigned to receive professional oral hygiene followed by 14 days of adjunctive use of either the MicroRepair® ABX mouthwash or the 0.12% CHX mouthwash.
The primary endpoint is the reduction in gingival bleeding, assessed by the Full-Mouth Bleeding Score (FMBS). Secondary outcomes include changes in dental plaque accumulation (Full-Mouth Plaque Score, FMPS), probing pocket depth (PPD), clinical attachment level (CAL), gingival recession (REC), salivary levels of active matrix metalloproteinase-8 (aMMP-8), tooth staining assessed by the Modified Lobene Stain Index, dentinal hypersensitivity assessed by the Schiff Air Index, and patient-reported outcomes related to oral perception and tolerability.
Participants will be followed at 2 weeks, 1 month, 3 months, and 6 months. This study is designed to evaluate whether the tested multi-component mouthwash provides clinical and biological outcomes comparable to those of chlorhexidine when used as an adjunct to professional oral hygiene in the management of plaque-induced gingivitis.
590 studies on the registry are indexed under Gingivitis; 105 are open to participants now.
This study's enrollment of 40 is below the median of 64 across 478 interventional studies indexed under Gingivitis.
Browse Gingivitis studies →University of Pavia is the lead sponsor of 141 studies on the registry; 39 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Participants assigned to the experimental group will undergo baseline clinical assessments (T0) followed by professional supragingival prophylaxis according to the Guided Biofilm Therapy (GBT) protocol. Standardized oral hygiene instructions will be provided. Participants will then use a MicroRepair® ABX mouthwash, containing cetylpyridinium chloride, magnolol, honokiol, and biomimetic hydroxyapatite, twice daily for 14 days.
Drug: MicroRepair ABX mouthwash
Participants assigned to the comparator group will undergo baseline clinical assessments (T0), followed by professional supragingival prophylaxis performed according to the Guided Biofilm Therapy (GBT) protocol, including plaque disclosure, ultrasonic instrumentation (EMS Piezon), and air polishing with glycine powder. Standardized oral hygiene instructions will be provided. After this initial phase, participants will be instructed to use a 0.12% chlorhexidine (CHX) mouthwash twice daily for 14 days.
Drug: Chlorhexidine 0.12% mouthwash
Participants begin at T0 (baseline) with clinical assessments, oral hygiene instruction, and the start of a 14-day home regimen using MicroRepair® ABX mouthwash. The formulation contains zinc-hydroxyapatite with antibacterial agents (cetylpyridinium chloride, magnolol, honokiol). Mouthwash is used twice daily (10 mL for 30 seconds) without rinsing, and participants avoid food or drink for 1 hour afterward. All participants use the same sodium lauryl sulfate (SLS)-free toothpaste (Biorepair®) throughout the study.
Also known as: MicroRepair® ABX
Participants begin at T0 (baseline) with clinical assessments, oral hygiene instruction, and the start of a 14-day home regimen using 0.12% chlorhexidine (CHX) mouthwash. Mouthwash is used twice daily (10 mL for 30 seconds) without rinsing, and participants avoid food or drink for 1 hour afterward. All participants use the same SLS-free toothpaste (Biorepair®) throughout the study.
Also known as: Chlorhexidine 0.12%
Change in gingival inflammation assessed by Full Mouth Bleeding Score (FMBS)
FMBS measures the percentage of bleeding sites after gentle probing at four sites per tooth (mesial, buccal, distal, lingual). It reflects the presence and severity of gingival inflammation. Scores range from 0% (no bleeding) to 100% (bleeding at all sites). A higher FMBS indicates more severe gingival inflammation. Comparison of FMBS over time will be used to assess clinical response to treatment.
Time frame: Baseline (T0), 2 weeks (T1), 1 month (T2), 3 months (T3), 6 months (T4)
Change in plaque accumulation assessed by Full Mouth Plaque Score (FMPS)
The Full Mouth Plaque Score (FMPS) quantifies the percentage of tooth surfaces with visible dental plaque, assessed after plaque disclosure at four sites per tooth (mesial, buccal, distal, lingual). The score is calculated as the number of plaque-positive sites divided by the total number of sites ×100. Scores range from 0% (no plaque) to 100% (plaque on all surfaces). Lower scores indicate better oral hygiene. FMPS will be compared between groups across time points.
Time frame: Baseline (T0), 2 weeks (T1), 1 month (T2), 3 months (T3), 6 months (T4)
Change in periodontal probing depth assessed by Probing Pocket Depth (PPD)
Periodontal probing depth (PPD) is defined as the distance from the gingival margin to the bottom of the gingival sulcus or periodontal pocket, measured in millimeters using a calibrated periodontal probe (Hu-Friedy PCP UNC 15). PPD is assessed at six sites per tooth (mesiobuccal, midbuccal, distobuccal, mesiolingual, midlingual, distolingual). For each participant, a mean PPD value is calculated at each time point. Typical scores range from 1 mm (healthy sulcus) to ≥7 mm (advanced pocket), with higher values indicating more severe periodontal inflammation or attachment loss. The primary endpoint is the change in mean PPD from baseline (T0) to 6 months (T4), comparing the two intervention groups: MicroRepair® ABX mouthwash regimen versus 0.12% chlorhexidine (CHX) mouthwash regimen.
Time frame: Baseline (T0), 2 weeks (T1), 1 month (T2), 3 months (T3), 6 months (T4)
Change in clinical attachment level assessed by Clinical Attachment Level (CAL)
Clinical Attachment Level (CAL) is the distance from the cemento-enamel junction (CEJ) to the bottom of the gingival sulcus or periodontal pocket, measured in millimeters at six sites per tooth with a calibrated periodontal probe (Hu-Friedy PCP UNC 15). Scores typically range from 0 mm (healthy attachment) to ≥7 mm (severe attachment loss). Higher values indicate more severe periodontal damage. CAL will be compared between groups across time points.
Time frame: Baseline (T0), 2 weeks (T1), 1 month (T2), 3 months (T3), 6 months (T4)
Change in gingival recession assessed by Recession (REC)
Gingival Recession (REC) is defined as the distance in millimeters between the cemento-enamel junction (CEJ) and the gingival margin, measured at six sites per tooth with a calibrated periodontal probe. Scores typically range from 0 mm (no recession) to ≥5 mm (advanced recession). Higher values indicate greater apical migration of the gingival margin. REC will be compared between groups across time points.
Time frame: Baseline (T0), 2 weeks (T1), 1 month (T2), 3 months (T3), 6 months (T4)
Change in extrinsic staining assessed by Modified Lobene Stain Index (MLSI)
The Modified Lobene Stain Index (MLSI) assesses extrinsic tooth staining on buccal and lingual/palatal surfaces. Each surface is scored for stain area and intensity, with total scores ranging from 0 (no stain) to 3 (severe stain). Higher scores indicate more pronounced extrinsic discoloration. Index scores will be compared between groups across time points.
Time frame: Baseline (T0), 2 weeks (T1), 1 month (T2), 3 months (T3), 6 months (T4)
Change in dentin hypersensitivity assessed by Schiff Air Index (SAI)
The Schiff Air Index (SAI) measures dentinal hypersensitivity in response to an air stimulus applied to the cervical area of the tooth. Scores range from 0 (no response) to 3 (painful response and request to stop). Higher scores indicate greater dentinal hypersensitivity. Scores will be compared between groups across time points.
Time frame: Baseline (T0), 2 weeks (T1), 1 month (T2), 3 months (T3), 6 months (T4)
Change in salivary inflammation assessed by activated Matrix Metalloproteinase-8 (aMMP-8) levels
Active matrix metalloproteinase-8 (aMMP-8) is a salivary biomarker of periodontal inflammation, measured with a commercial immunoenzymatic test (aMMP-8 Test®, Biomolecular Diagnostic). Results are expressed in nanograms per milliliter (ng/mL). Reference ranges: \<8 ng/mL = no inflammation; 9-19 ng/mL = mild inflammation; ≥20 ng/mL = severe inflammation. aMMP-8 levels will be compared between groups from baseline (T0) to 2 weeks (T1).
Time frame: Baseline (T0), 2 weeks (T1)
Change in taste perception assessed by a validated taste alteration questionnaire
Taste perception will be evaluated using a validated patient-reported questionnaire that explores the presence and severity of taste alterations (e.g., bitter, metallic, or unpleasant taste). Each item is scored on a 5-point Likert scale: 0 = no alteration, 1 = mild alteration, 2 = moderate alteration, 3 = severe alteration, 4 = very severe alteration. The total score reflects the degree of dysgeusia perceived by the patient. Mean scores will be compared between groups at each time point to assess tolerability of the mouthwashes.
Time frame: 2 weeks (T1), 1 month (T2), 3 months (T3), 6 months (T4)
Plan to share: No — Data will be available upon motivated request to the corresponding authors.
No publications or documents are linked to this record.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Pavia